Particle therapy tumour outcomes: An updated systematic review.
carbon ion therapy
hadron therapy
particle therapy
proton therapy
systematic review
Journal
Journal of medical imaging and radiation oncology
ISSN: 1754-9485
Titre abrégé: J Med Imaging Radiat Oncol
Pays: Australia
ID NLM: 101469340
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
22
08
2019
revised:
20
12
2019
accepted:
13
02
2020
pubmed:
10
4
2020
medline:
29
6
2021
entrez:
10
4
2020
Statut:
ppublish
Résumé
Particle therapy (PT) offers the potential for reduced normal tissue damage as well as escalation of target dose, thereby enhancing the therapeutic ratio in radiation therapy. Reflecting the building momentum of PT use worldwide, construction has recently commenced for The Australian Bragg Centre for Proton Therapy and Research in Adelaide - the first PT centre in Australia. This systematic review aims to update the clinical evidence base for PT, both proton beam and carbon ion therapy. The purpose is to inform clinical decision-making for referral of patients to PT centres in Australia as they become operational and overseas in the interim. Three major databases were searched by two independent researchers, and evidence quality was classified according to the National Health and Medical Research Council evidence hierarchy. One hundred and thirty-six studies were included, two-thirds related to proton beam therapy alone. PT at the very least provides equivalent tumour outcomes compared to photon controls with the possibility of improved control in the case of carbon ion therapy. There is suggestion of reduced morbidities in a range of tumour sites, supporting the predictions from dosimetric modelling and the wide international acceptance of PT for specific indications based on this. Though promising, this needs to be counterbalanced by the overall low quality of evidence found, with 90% of studies of level IV (case series) evidence. Prospective comparative clinical trials, supplemented by database-derived outcome information, preferably conducted within international and national networks, are strongly recommended as PT is introduced into Australasia.
Identifiants
pubmed: 32270626
doi: 10.1111/1754-9485.13021
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
711-724Informations de copyright
© 2020 The Royal Australian and New Zealand College of Radiologists.
Références
Durante M, Orecchia R, Loeffler JS. Charged-particle therapy in cancer: clinical uses and future perspectives. Nat Rev Clin Oncol 2017; 14: 483-95.
Haefner MF, Verma V, Bougatf N et al. Dosimetric comparison of advanced radiotherapy approaches using photon techniques and particle therapy in the postoperative management of thymoma. Acta Oncol 2018; 57: 1713-20.
van de Water TA, Bijl HP, Schilstra C, Pijls-Johannesma M, Langendijk JA. The potential benefit of radiotherapy with protons in head and neck cancer with respect to normal tissue sparing: a systematic review of literature. Oncologist 2011; 16: 366-77.
Takizawa D, Mizumoto M, Yamamoto T et al. A comparative study of dose distribution of PBT, 3D-CRT and IMRT for pediatric brain tumors. Radiat Oncol 2017; 12: 40.
Paulino AC, Mahajan A, Ye R et al. Ototoxicity and cochlear sparing in children with medulloblastoma: proton vs. photon radiotherapy. Radiother Oncol 2018; 128: 128-32.
Holliday EB, Kocak-Uzel E, Feng L et al. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: a case-matched control analysis. Med Dosim 2016; 41: 189-94.
Matsumoto K, Nakamura K, Shioyama Y et al. Treatment planning comparison for carbon ion radiotherapy, proton therapy and intensity-modulated radiotherapy for spinal sarcoma. Anticancer Res 2015; 35: 4083-9.
PTCOG. Particle Therapy Co-Operative Group Official Webpage. Available from: https://www.ptcog.ch/. Accessed on 6/3/19.
Stone HB, Coleman CN, Anscher MS, McBride WH. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 2003; 4: 529-36.
Stewart FA, Akleyev AV, Hauer-Jensen M et al. ICRP publication 118: ICRP statement on tissue reactions and early and late effects of radiation in normal tissues and organs - threshold doses for tissue reactions in a radiation protection context. Ann ICRP 2012; 41: 1-322.
Baselet B, Rombouts C, Benotmane AM, Baatout S, Aerts A. Cardiovascular diseases related to ionizing radiation: the risk of low-dose exposure (Review). Int J Mol Med 2016; 38: 1623-41.
Sachs RK, Shuryak I, Brenner D, Fakir H, Hlatky L, Hahnfeldt P. Second cancers after fractionated radiotherapy: stochastic population dynamics effects. J Theor Biol 2007; 249: 518-31.
Lomax AJ, Bortfeld T, Goitein G et al. A treatment planning inter-comparison of proton and intensity modulated photon radiotherapy. Radiother Oncol 1999; 51: 257-71.
Washington State Health Care Authority. Proton Beam Therapy Final Evidence Report: Health Technology Assessment Program (HTA); 2014 [updated 28-03-2014]. Available from URL: https://icer-review.org/wp-content/uploads/2014/07/pbt_final_report_040114.pdf. Accessed on 5/4/19.
Mishra MV, Aggarwal S, Bentzen SM, Knight N, Mehta MP, Regine WF. Establishing evidence-based indications for proton therapy: an overview of current clinical trials. Int J Radiat Oncol Biol Phys 2017; 97: 228-35.
Leroy R, Benahmed N, Hulstaert F, Van Damme N, De Ruysscher D. Proton therapy in children: a systematic review of clinical effectiveness in 15 pediatric cancers. Int J Radiat Oncol Biol Phys 2016; 95: 267-78.
Ofuya M, McParland L, Murray L, Brown S, Sebag-Montefiore D, Hall E. Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy. Clin Trans Rad Oncol 2019; 19: 17-26.
Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Med 2009; 6: e1000100.
De Ruysscher D, Mark Lodge M, Jones B et al. Charged particles in radiotherapy: a 5-year update of a systematic review. Radiother Oncol 2012; 103: 5-7.
Lodge M, Pijls-Johannesma M, Stirk L, Munro AJ, De Ruysscher D, Jefferson T. A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer. Radiother Oncol 2007; 83: 110-22.
National Health and Medical Research Council, Australian Government. NHMRC additional levels of evidence and grades for recommendations 2009. Available from URL: https://www.mja.com.au/sites/default/files/NHMRC.levels.of.evidence.2008-09.pdf. Accessed on 4/5/19.
Bush DA, Smith JC, Slater JD et al. Randomized clinical trial comparing proton beam radiation therapy with transarterial chemoembolization for hepatocellular carcinoma: results of an interim analysis. Int J Radiat Oncol Biol Phys 2016; 95: 477-82.
Liao Z, Lee JJ, Komaki R et al. Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer. J Clin Oncol 2018; 36: 1813-22.
Char DH, Quivey JM, Castro JR, Kroll S, Phillips T. Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial. Ophthalmology 1993; 100: 1547-54.
Shipley WU, Verhey LJ, Munzenrider JE et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995; 32: 3-12.
Linstadt D, Quivey JM, Castro JR et al. Comparison of helium-ion radiation therapy and split-course megavoltage irradiation for unresectable adenocarcinoma of the pancreas. Final report of a Northern California Oncology Group randomized prospective clinical trial. Radiology 1988; 168: 261-4.
Zietman AL, DeSilvio ML, Slater JD et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005; 294: 1233-9.
Gragoudas ES, Lane AM, Regan S et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. Arch Ophthalmol 2000; 118: 773-8.
Kim YJ, Cho KH, Pyo HR et al. A phase II study of hypofractionated proton therapy for prostate cancer. Acta Oncol 2013; 52: 477-85.
Zietman AL, Bae K, Slater JD et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/American college of radiology 95-09. J Clin Oncol 2010; 28: 1106-11.
Santoni R, Liebsch N, Finkelstein DM et al. Temporal lobe (TL) damage following surgery and high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosarcomas of the base of the skull. Int J Radiat Oncol Biol Phys 1998; 41: 59-68.
Desjardins L, Lumbroso-Le Rouic L, Levy-Gabriel C et al. Combined proton beam radiotherapy and transpupillary thermotherapy for large uveal melanomas: a randomized study of 151 patients. Ophthalmic Res 2006; 38: 255-60.
Rutz HP, Weber DC, Sugahara S et al. Extracranial chordoma: outcome in patients treated with function-preserving surgery followed by spot-scanning proton beam irradiation. Int J Radiat Oncol Biol Phys 2007; 67: 512-20.
Yoon SS, Chen YL, Kirsch DG et al. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. Ann Surg Oncol 2010; 17: 1515-29.
Park L, Delaney TF, Liebsch NJ et al. Sacral chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 2006; 65: 1514-21.
Blanchard P, Garden AS, Gunn GB et al. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - a case matched analysis. Radiother Oncol 2016; 120: 48-55.
Mizoe JE, Hasegawa A, Bessho H. Phase II clinical trial for mucosal malignant melanoma of the head and neck combined with chemotherapy (protocol 0007). NIRS-ETOILE: joint symposium 2009 on carbon ion radiotherapy; Lyon 2009. Conference presentation (unpublished work).
Sato M, Gunther JR, Mahajan A et al. Progression-free survival of children with localized ependymoma treated with intensity-modulated radiation therapy or proton-beam radiation therapy. Cancer 2017; 123: 2570-8.
Eaton BR, Esiashvili N, Kim S et al. Clinical outcomes among children With standard-risk medulloblastoma treated with proton and photon radiation therapy: a comparison of disease control and overall survival. Int J Radiat Oncol Biol Phys 2016; 94: 133-8.
Chen YL, Liebsch N, Kobayashi W et al. Definitive high-dose photon/proton radiotherapy for unresected mobile spine and sacral chordomas. Spine (Phila Pa 1976); 2013; 38: E930-6.
Ciernik IF, Niemierko A, Harmon DC et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 2011; 117: 4522-30.
Staab A, Rutz HP, Ares C et al. Spot-scanning-based proton therapy for extracranial chordoma. Int J Radiat Oncol Biol Phys 2011; 81: e489-96.
Pennicooke B, Laufer I, Sahgal A et al. Safety and local control of radiation therapy for chordoma of the spine and sacrum: a systematic review. Spine (Phila Pa 1976) 2016; 41 (Suppl. 20): S186-S92.
Lesueur P, Calugaru V, Nauraye C et al. Proton therapy for treatment of intracranial benign tumors in adults: a systematic review. Cancer Treat Rev 2019; 72: 56-64.
Kahn J, Loeffler JS, Niemierko A, Chiocca EA, Batchelor T, Chakravarti A. Long-term outcomes of patients with spinal cord gliomas treated by modern conformal radiation techniques. Int J Radiat Oncol Biol Phys 2011; 81: 232-8.
Bush DA, Kayali Z, Grove R, Slater JD. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer 2011; 117: 3053-9.
Holliday EB, Esmaeli B, Pinckard J et al. A multidisciplinary orbit-sparing treatment approach that includes proton therapy for epithelial tumors of the orbit and ocular adnexa. Int J Radiat Oncol Biol Phys 2016; 95: 344-52.
Verma V, Mehta MP. Clinical outcomes of proton radiotherapy for uveal melanoma. Clin Oncol (R Coll Radiol) 2016; 28: e17-27.
Wang Z, Nabhan M, Schild SE et al. Charged particle radiation therapy for uveal melanoma: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 2013; 86: 18-26.
Group COMS. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS Report No. 28. JAMA Ophthalmol 2006; 124: 1684-93.
Hayashi Y, Nakamura T, Mitsudo K et al. Re-irradiation using proton beam therapy combined with weekly intra-arterial chemotherapy for recurrent oral cancer. Asia Pac J Clin Oncol 2017; 13: e394-e401.
Guttmann DM, Frick MA, Carmona R et al. A prospective study of proton reirradiation for recurrent and secondary soft tissue sarcoma. Radiother Oncol 2017; 124: 271-6.
Eaton BR, Chowdhry V, Weaver K et al. Use of proton therapy for re-irradiation in pediatric intracranial ependymoma. Radiother Oncol 2015; 116: 301-8.
Combs SE, Kalbe A, Nikoghosyan A et al. Carbon ion radiotherapy performed as re-irradiation using active beam delivery in patients with tumors of the brain, skull base and sacral region. Radiother Oncol 2011; 98: 63-7.
El Shafie RA, Czech M, Kessel KA et al. Evaluation of particle radiotherapy for the re-irradiation of recurrent intracranial meningioma. Radiat Oncol 2018; 13: 86.
Marucci L, Ancukiewicz M, Lane AM, Collier JM, Gragoudas ES, Munzenrider JE. Uveal melanoma recurrence after fractionated proton beam therapy: comparison of survival in patients treated with reirradiation or with enucleation. Int J Radiat Oncol Biol Phys 2011; 79: 842-6.
Oshiro Y, Mizumoto M, Okumura T et al. Analysis of repeated proton beam therapy for patients with hepatocellular carcinoma. Radiother Oncol 2017; 123: 240-5.
Verma V, Rwigema JM, Malyapa RS, Regine WF, Simone CB 2nd. Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation. Radiother Oncol 2017; 125: 21-30.
Outani H, Hamada K, Imura Y et al. Comparison of clinical and functional outcome between surgical treatment and carbon ion radiotherapy for pelvic chondrosarcoma. Int J Clin Oncol 2016; 21: 186-93.
Aarhus University Hospital. The Danish National Center for Particle Radiotherapy 2012. Available from URL: https://www.rm.dk/siteassets/om-os/a_udbud/dnu_partikelterapi/det-nationale-center-for-partikelterapi-2012.pdf. Accessed on 12/3/19.
NHS England. NHS commissioning: Specialised services - Proton beam therapy 2019 Available from URL: https://www.england.nhs.uk/commissioning/spec-services/highly-spec-services/pbt/. Accessed on 12/3/19.
Goetz G, Mitic M, Mittermayr T, Wild C. Health technology assessment of carbon-ion beam radiotherapy: a systematic review of clinical effectiveness and safety for 54 oncological indications in 12 tumour regions. Anticancer Res 2019; 39: 1635-50.
Mohamad O, Yamada S, Durante M. Clinical indications for carbon ion radiotherapy. Clin Oncol (R Coll Radiol) 2018; 30: 317-29.
Durante M, Debus J. Heavy charged particles: Does improved precision and higher biological effectiveness translate to better outcome in patients? Semin Radiat Oncol 2018; 28: 160-7.
Kong FS. What happens when proton meets randomization: Is there a future for proton therapy? J Clin Oncol 2018; 36: 1777-9.
Macbeth FR, Williams MV. Proton therapy should be tested in randomized trials. J Clin Oncol 2008; 26: 2590-1; author reply 3-6.
Glatstein E, Glick J, Kaiser L, Hahn SM. Should randomized clinical trials be required for proton radiotherapy? An alternative view. J Clin Oncol 2008; 26: 2438-9.
Halperin EC. Randomized prospective trials of innovative radiotherapy technology are necessary. J Am Coll Radiol 2009; 6: 33-7.
Group CPBCTS. Proton beam therapy - the challenges of delivering high-quality evidence of clinical benefit. Clin Oncol (R Coll Radiol) 2018; 30: 280-4.
Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy? J Clin Oncol 2008; 26: 175-6.
Glimelius B, Montelius A. Proton beam therapy; Do we need the randomised trials and can we do them? Radiother Oncol 2007; 83: 105-9.
Bekelman JE, Denicoff A, Buchsbaum J. Randomized trials of proton therapy: Why they are at risk, proposed solutions, and implications for evaluating advanced technologies to diagnose and treat cancer. J Clin Oncol 2018; 36: 2461-4.
Bentzen SM. Randomized controlled trials in health technology assessment: overkill or overdue? Radiother Oncol 2008; 86: 142-7.
Foroughi S, Wong HL, Gately L et al. Registry-based randomized clinical trials as a method to improve cancer care in Australia. Asia Pac J Clin Oncol 2019; 15: 188-9.
Kahalley LS, Peterson R, Ris MD et al. Superior intellectual outcomes after proton radiotherapy compared with photon radiotherapy for pediatric medulloblastoma. J Clin Oncol 2019: JCO.19.01706.
Duchesne GM, Grand M, Kron T et al. Trans Tasman radiation oncology group: development of the assessment of new radiation oncology technology and treatments (ANROTAT) framework. J Med Imaging Radiat Oncol 2015; 59: 363-70.
Langendijk JA, Lambin P, De Ruysscher D, Widder J, Bos M, Verheij M. Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach. Radiother Oncol 2013; 107: 267-73.
Delaney AR, Dahele M, Tol JP, Kuijper IT, Slotman BJ, Verbakel W. Using a knowledge-based planning solution to select patients for proton therapy. Radiother Oncol 2017; 124: 263-70.
Odei BCL, Boothe D, Keole SR et al. A 20-year analysis of clinical trials involving proton beam therapy. Int J Part Therapy 2016; 3: 398-406.
ASTRO. ASTRO updates insurance coverage recommendations for proton therapy - American Society for Radiation Oncology 2017. Available from URL: https://www.astro.org/News-and-Publications/News-and-Media-Center/News-Releases/2017/ASTRO-updates-insurance-coverage-recommendations-for-proton-therapy/. Accessed on 20/6/19.
Hirano Y, Onozawa M, Hojo H et al. Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma. Radiation Oncol 2018; 13: 23.
Grant SR, Grosshans DR, Bilton SD et al. Proton versus conventional radiotherapy for pediatric salivary gland tumors: acute toxicity and dosimetric characteristics. Radiother Oncol 2015; 116: 309-15.
Shiraishi Y, Xu C, Yang J, Komaki R, Lin SH. Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy. Radiother Oncol 2017; 125: 48-54.
Goitein M. Trials and tribulations in charged particle radiotherapy. Radiother Oncol 2010; 95: 23-31.
Flanz J, Bortfeld T. Evolution of technology to optimize the delivery of proton therapy: the third generation. Semin Radiat Oncol 2013; 23: 142-8.
Miller RC, Lodge M, Murad MH, Jones B. Controversies in clinical trials in proton radiotherapy: the present and the future. Semin Radiat Oncol 2013; 23: 127-33.
Vyfhuis MAL, Onyeuku N, Diwanji T et al. Advances in proton therapy in lung cancer. Therap Advanc Res Dis 2018; 12: 1753466618783878.
Unkelbach J, Paganetti H. Robust proton treatment planning: physical and biological optimization. Semin Radiat Oncol 2018; 28: 88-96.
Paganetti H, Giantsoudi D. Relative biological effectiveness uncertainties and implications for beam arrangements and dose constraints in proton therapy. Semin Radiat Oncol 2018; 28: 256-63.
Shah A, Efstathiou JA, Paly JJ et al. Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012; 83: e13-9.
Langendijk JA, Orecchia R, Haustermans K et al. Prospective data registration and clinical trials for particle therapy in Europe. Radiother Oncol 2018; 128: 9-13.
Grau C, Baumann M, Weber DC. Optimizing clinical research and generating prospective high-quality data in particle therapy in Europe: Introducing the European Particle Therapy Network (EPTN). Radiother Oncol 2018; 128: 1-3.
Hess CB, Indelicato DJ, Paulino AC et al. An update from the Pediatric Proton Consortium Registry. Front Oncol 2018; 8: 165.
Berrington de Gonzalez A, Vikram B, Buchsbaum JC et al. A Clarion call for large-scale collaborative studies of pediatric proton therapy. Int J Radiat Oncol Biol Phys 2017; 98: 980-1.